In a study published in The Lancet, Europe's NeuroSearch announced strong Phase II for tesofensine, the company's anti-obesity compound. The hunger-suppressing drug produced a weight loss twice that of currently approved obesity drugs Reductil/Meridia and Acomplia. "The results indicate that obese patients who typically obtain a weight loss of 3-5 kg with existing drugs on the market, can now expect a weight loss of 10 kg with tesofensine alone. If, in addition, the treatment is combined with the right diet, the total weight loss can amount to 20 kg," said Arne Astrup, one of the study's authors. NeuroSearch is planning to move the drug into Phase III trials.
- see NeuroSearch's release for more
ALSO: Bad news for Sanofi: The company has withdrawn Acomplia from the European markets following an EMEA recommendation that the company suspend sales of the drug due to safety concerns. Report